PCVX Quote, Financials, Valuation and Earnings

CEL-SCI has a net margin of -- compared to Vaxcyte's net margin of --. Vaxcyte's return on equity of -- beat CEL-SCI's return on equity of --.

Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand CEL-SCI has an analysts' consensus of $7.73 which suggests that it could grow by 1787.1%. Given that CEL-SCI has higher upside potential than Vaxcyte, analysts believe CEL-SCI is more attractive than Vaxcyte.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.653, suggesting its less volatile than the S&P 500 by 34.718%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. Vaxcyte's net income of -$103.1M is lower than CEL-SCI's net income of -$6.9M. Notably, Vaxcyte's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma has a net margin of -- compared to Vaxcyte's net margin of -416.75%. Vaxcyte's return on equity of -- beat IGC Pharma's return on equity of -137.43%.

Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand IGC Pharma has an analysts' consensus of $3.63 which suggests that it could grow by 1026.13%. Given that IGC Pharma has higher upside potential than Vaxcyte, analysts believe IGC Pharma is more attractive than Vaxcyte.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma has a beta of 1.325, suggesting its more volatile than the S&P 500 by 32.462%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than IGC Pharma quarterly revenues of $412K. Vaxcyte's net income of -$103.1M is lower than IGC Pharma's net income of -$1.7M. Notably, Vaxcyte's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 19.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Vaxcyte's net margin of -49.65%. Vaxcyte's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 447.79%. Given that NovaBay Pharmaceuticals has higher upside potential than Vaxcyte, analysts believe NovaBay Pharmaceuticals is more attractive than Vaxcyte.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vaxcyte pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vaxcyte's net income of -$103.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vaxcyte's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Vaxcyte's net margin of 25.23%. Vaxcyte's return on equity of -- beat Pfizer's return on equity of 4.63%.

Vaxcyte has a consensus price target of $149.89, signalling upside risk potential of 67.87%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 18.9%. Given that Vaxcyte has higher upside potential than Pfizer, analysts believe Vaxcyte is more attractive than Pfizer.

Vaxcyte has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Vaxcyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.41% to investors and pays a quarterly dividend of $0.42 per share. Vaxcyte pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Vaxcyte quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $17.7B. Vaxcyte's net income of -$103.1M is lower than Pfizer's net income of $4.5B. Notably, Vaxcyte's price-to-earnings ratio is -- while Pfizer's PE ratio is 35.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vaxcyte is -- versus 2.51x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.